Filing Details

Accession Number:
0001179110-14-012736
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-12 13:51:23
Reporting Period:
2014-08-08
Filing Date:
2014-08-12
Accepted Time:
2014-08-12 13:51:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1065087 Albany Molecular Research Inc AMRI Services-Commercial Physical & Biological Research (8731) 141742717
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1449207 R Steven Hagen 26 Corporate Circle
Albany NY 12203
Svp Pharmaceutical Dev & Mfg No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-08-08 797 $18.99 30,933 No 4 S Direct
Common Stock Acquisiton 2014-08-08 10,000 $5.25 40,933 No 4 M Direct
Common Stock Disposition 2014-08-08 10,000 $18.99 30,933 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Acquisiton 2014-08-08 10,000 $5.25 10,000 $5.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,250 2021-06-02 No 4 M Direct
Footnotes
  1. 100% of grant is time based. Time based grant vests 25% per year on each of the first 4 anniversaries of the date of grant (June 2, 2011). Performance based grant vests 25% per year on each of the first 4 anniversaries of the grant date if (1) certain performance criteria related to the Company's operating profitabilityare reached and (2) the grantee is employed on such anniversary date; if the foregoing criteria are not met on any anniversary date, 25% of the shares of options under theperformance award will immediately be forfeited. The 10,000 shares being exercised represent a portion of the vested grants. 25% of the initial grant is not yet exercisable.
  2. 2. The reported price represents the weighted average sales price for such shares. The actual range of sales prices for such shares was $18.89 - $19.14. Upon request of the Commission, the exact number of shares sold at each price will be provided.